Skip to main content

Advertisement

SpringerLink
Log in

RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a cancer cell-surface antigen and has been identified as a prognostic factor in several cancers. It is thought that tumor cells escape from immune attack by expressing RCAS1, which induces apoptosis in receptor-positive immune cells. We investigated the relationship between RCAS1 expression and clinicopathologic features and clinical outcome in patients with extrahepatic bile duct carcinoma (EBDC) who underwent curative resection.

Methods

RCAS1 expression was determined by immunohistochemistry in 60 patients with EBDC who underwent curative resection from 1992 to 1999. The patients were divided into two groups on the basis of the extent of RCAS1 expression: a low-expression group (immunoreactivity in <25% of cells) and a high-expression group. Expression was correlated with clinicopathologic features and prognosis.

Results

RCAS1 was expressed in 52 (86.7%) of 60 tumors and at a high frequency in all histopathologic stages. High expression of RCAS1 was detected in 46 (76.7%) of 60 cases. No correlation existed between the pattern of RCAS1 expression and any clinicopathologic feature, although high expression did correlate with poor prognosis. High RCAS1 expression was an independent negative predictor for survival.

Conclusions

RCAS1 expression predicts poor outcome in resectable EBDC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Langer JC, Langer B, Taylor BR, Zeldin R, Cummings B. Carcinoma of the extrahepatic bile ducts: results of an aggressive surgical approach.Surgery 1985;98:752–9.

    PubMed  CAS  Google Scholar 

  2. Reding R, Buard JL, Lebeau G, Launois B. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded): results of the French Surgical Association Survey.Ann Surg 1991;213:236–41.

    Article  PubMed  CAS  Google Scholar 

  3. Schoenthaler R, Philips TL, Castro J, Efird JT, Better A, Way LW. Carcinoma of the extrahepatic bile ducts: the University of California at San Francisco experience.Ann Surg 1994;219:267–74.

    Article  PubMed  CAS  Google Scholar 

  4. Doglietto GB, Alfieri S, Pacelli F, et al. Extrahepatic bile duct carcinoma: a western experience with 118 consecutive patients.Hepatogastroenterology 2000;47:349–54.

    PubMed  CAS  Google Scholar 

  5. Tompkins RK, Saunders K, Roslyn JJ, Longmire WP Jr. Changing patterns in diagnosis and management of bile duct cancer.Ann Surg 1990;211:614–21.

    PubMed  CAS  Google Scholar 

  6. Bhuiya MR, Nimura Y, Kamiya J, et al. Clinicopathologic studies on perineural invasion of bile duct carcinoma.Ann Surg 1992;215:344–9.

    Article  PubMed  CAS  Google Scholar 

  7. Nishida T, Nakao K, Hamaji M, Nakahara MA, Tsujimoto M, Prognostic significance of proliferative cell nuclear antigen in carcinoma of the extrahepatic bile duct.World J Surg 1997;21: 634–9.

    Article  PubMed  CAS  Google Scholar 

  8. Hui AM, Cui X, Makuuchi M, Li X, Shi YZ, Takayama T. Decreased p27(Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma.Hepatology 1999;30:1167–73.

    Article  PubMed  CAS  Google Scholar 

  9. Suto T, Sugai T, Nakamura S, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.Cancer 1998;82:86–95.

    Article  PubMed  CAS  Google Scholar 

  10. Yokoyama Y, Hiyama E, Murakami Y, Matsuura Y, Yokoyama T. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.Cancer 1999;86:1691–9.

    Article  PubMed  CAS  Google Scholar 

  11. Hida Y, Morita T, Fujita M, et al. Vascular endothelial growth factor expression is an indeendent negative predictor in extrahepatic biliary tract carcinomas.Anticancer Res 1999;19:2257–60.

    PubMed  CAS  Google Scholar 

  12. Li X, Hui AM, Takayama T, Cui X, Shi Y, Makuuchi M. Altered p21 (WAF1/CIP1) expression is associated with poor prognosis in extrahepatic bile duct carcinoma.Cancer Lett 2000;154:85–91.

    Article  PubMed  CAS  Google Scholar 

  13. Sonoda K, Nakashima M, Saito T, et al. Establishment of a new human uterine cervical adenocarcinoma cell line, SiSo, and its reactivity to anticancer reagents.Int J Oncol 1995;6:1099–104.

    Google Scholar 

  14. Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas.Cancer 1996;77:1501–9.

    Article  PubMed  CAS  Google Scholar 

  15. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1.Nat Med 1999;5:938–42.

    Article  PubMed  CAS  Google Scholar 

  16. Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias.Clin Cancer Res 1998;4:1517–20.

    PubMed  CAS  Google Scholar 

  17. Kaku T, Sonoda K, Kamura T, et al. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix.Clin Cancer Res 1999;5:1449–53.

    PubMed  CAS  Google Scholar 

  18. Iwasaki T, Nakashima M, Watanabe T, et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1.Int J Cancer 2000;89:488–93.

    Article  PubMed  CAS  Google Scholar 

  19. Sobin LH, Wittekind C,TNM Classification of Malignant Tumors, 5th ed. New York: Wiley-Liss, Inc., 1997;81–3

    Google Scholar 

  20. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion?.Nat Med 1996;2:1361–6.

    Article  PubMed  CAS  Google Scholar 

  21. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.Science 1996;274:1363–6.

    Article  PubMed  CAS  Google Scholar 

  22. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express. Fas ligand.Cancer Res 1997;57:1007–12.

    PubMed  CAS  Google Scholar 

  23. Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.Cancer Res 1998;58:1741–9.

    PubMed  CAS  Google Scholar 

  24. O’Connell J, Bennett MW, O’Sullivan GC, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.J Pathol 1998;186:240–6.

    Article  PubMed  CAS  Google Scholar 

  25. Bennett MW, O’Connell J, O’Sullivan GC, et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.Cut 1999;44:156–62.

    CAS  Google Scholar 

  26. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?Hepatology 1999;30:413–21.

    Article  PubMed  CAS  Google Scholar 

  27. Que FG, Phan VA, Phan VH, et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.Hepatology 1999;30:1398–404.

    Article  PubMed  CAS  Google Scholar 

  28. Oshikiri T, Hida Y, Miyamoto M, et al. RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer.Br J Cancer 2001;85:1922–7.

    Article  PubMed  CAS  Google Scholar 

  29. Hiraoka K, Hida Y, Miyamoto M, et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker.Int J Cancer (in press).

  30. Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis.Clin Cancer Res 1999;5:629–35

    PubMed  CAS  Google Scholar 

  31. Saurin JC, Joly-Pharaboz MO, Pernas P, Henry L, Ponchon T, Madjar JJ. Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures.Gut 2000;47:357–61.

    Article  PubMed  CAS  Google Scholar 

  32. Ikeda K, Sato M, Tsutsumi O, et al. Promoter analysis and chromosomal mapping of human EBAG9 gene.Biochem Biophys Res Commun 2000;273:654–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, 060-8648, Sapporo, Hokkaido, Japan

    Masato Suzuoki MD, Yasuhiro Hida MD, Masaki Miyamoto MD, Taro Oshikiri MD, Kei Hiraoka MD, Yoshihiro Nakakubo MD, Shunichi Okushiba MD, Satoshi Kondo MD & Hiroyuki Katoh MD

  2. Department of Pathology, Teinekeijinkai Hospital, Sapporo, Japan

    Toshiya Shinohara MD

  3. Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

    Tomoo Itoh MD

Authors
  1. Masato Suzuoki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhiro Hida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaki Miyamoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taro Oshikiri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kei Hiraoka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihiro Nakakubo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiya Shinohara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomoo Itoh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shunichi Okushiba MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Satoshi Kondo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroyuki Katoh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masato Suzuoki MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzuoki, M., Hida, Y., Miyamoto, M. et al. RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma. Annals of Surgical Oncology 9, 388–393 (2002). https://doi.org/10.1007/BF02573874

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02573874

Key Words

Search

Navigation